DYN

Dyne Therapeutics, Inc.

NasdaqHealthcarePharmaceutical Preparations

Insider activity for last month from 08/09 to 09/09. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Latest filingSep 08, 2026Most recent Form 4
Total buying$00 buys
Total selling$6.56B15 sells
Net open-market-$6.56B5 insiders
Open-market mix
Buy vs sell distribution by transaction count
15 transactions
0 buys0%·100%15 sells

Insider activity report

Monthly open-market purchase and sale counts
Buys Sells
1050-5-10transactionsAug 2026 sells: 10 transactions · $6.54B10AugSep 2026 sells: 5 transactions · $24.7M5Sep

Transaction codes

By Form 4 transaction code in selected period
15transactions
  • S · Open-market sells · dominant15 · 100%

Activity by reported role

A joint filing can contribute to multiple roles
17transactions
  • Director · dominant6 · 35%
  • CCO3 · 18%
  • CMO3 · 18%
  • Chief executive officer2 · 12%
  • PRES2 · 12%
  • Chief financial officer1 · 6%

Distinct insiders active

Reporting-owner CIKs by month · peak Aug 2026 (5)
Aug 2026Sep 2026
8distinct insiders in 2 months

Reported Holdings After

Separated by insider, security, and ownership type
Rhodes Jason PCommon Stock · Indirect · See footnote
3.8M428.9kAug 13, 2026 · 1,045,735 shares owned afterAug 13, 2026 · 751,411 shares owned afterAug 13, 2026 · 3,801,128 shares owned afterAug 14, 2026 · 567,358 shares owned afterAug 14, 2026 · 428,946 shares owned afterAug 14, 2026 · 2,441,454 shares owned afterAug 13, 2026Aug 14, 2026
2,441,454Aug 14, 2026
Kerr DouglasCommon Stock · Direct
167.6k162.6kAug 13, 2026 · 167,599 shares owned afterSep 04, 2026 · 163,854 shares owned afterSep 08, 2026 · 162,564 shares owned afterAug 13, 2026Sep 08, 2026
162,564Sep 08, 2026
Friedl-Naderer JohannaCommon Stock · Direct
154.0k152.9kAug 13, 2026 · 153,982 shares owned afterSep 04, 2026 · 153,082 shares owned afterSep 08, 2026 · 152,897 shares owned afterAug 13, 2026Sep 08, 2026
152,897Sep 08, 2026
Cox JohnCommon Stock · Direct
363.2k357.5kAug 13, 2026 · 363,165 shares owned afterSep 08, 2026 · 357,507 shares owned afterAug 13, 2026Sep 08, 2026
357,507Sep 08, 2026
Lucera ErickCommon Stock · Direct
119.8k119.8kAug 13, 2026 · 119,766 shares owned afterAug 13, 2026Aug 13, 2026
119,766Aug 13, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells red
0 active days
Aug 09Sep 09
LessMore

Filing detail checks

Secondary metrics for the selected period
Largest buy-
Largest sale$3.39B
10b5-1 detected15
Amended rows0

DYN transaction history

Filters apply within this company and selected period by default
Reset
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date

No transactions match your filters

Once the backend ingests and parses SEC filings, they will appear here. Try removing a filter or picking a wider date range.

Dyne Therapeutics, Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at Dyne Therapeutics, Inc.?

Friedl-Naderer Johanna, Kerr Douglas, Cox John, Rhodes Jason P, Lucera Erick.

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

Friedl-Naderer Johanna reported a sale on Sep 08, 2026 valued at $349k. Read the SEC filing.

What is the recent purchase and sale balance?

Net open-market selling in the selected period was $65,657,759.39. Sales can occur for many non-investment reasons.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.